市場調査レポート

末梢動脈疾患(PAD)治療の世界市場

Peripheral Arterial Disease (PAD) Therapeutics

発行 Global Industry Analysts, Inc. 商品コード 248879
出版日 ページ情報 英文 365 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
末梢動脈疾患(PAD)治療の世界市場 Peripheral Arterial Disease (PAD) Therapeutics
出版日: 2012年07月01日 ページ情報: 英文 365 Pages
概要

当レポートでは、末梢動脈疾患(PAD)治療の世界市場を取り上げ、米国、カナダ、欧州、アジア太平洋、ラテンアメリカおよびその他の地域など、地域ごとの個別分析を行うとともに、過去の実績/推定および予測、ならびにこれらの市場の過去6年間の分析を提供し、主要企業およびニッチ企業50社のプロフィールをまとめるなど、概略以下の構成でお届けします。

第1章 イントロダクション、調査方法、製品定義

  • 調査の信頼性とレポートの制約
  • 免責事項
  • データの解釈とレポートのレベル
    • 定量技法および分析法
  • 製品の定義と調査範囲

第2章 エグゼクティブサマリー

  • 産業概要
    • 低い認知度と薬剤の選択しにおける制約が象徴的なPAD市場
    • 重症肢虚血:洞察
    • 高齢化および生活様式に関連した問題に根差した発症率の増加がPAD市場の成長を促進
    • 高齢人口の拡大がPAD治療市場の土台を形成
    • 高いコスト:懸念の理由
    • 抗血小板薬:PADとの戦いを先導
    • Plavixは特許の期限切れにより形勢が不利に
    • Plavixの歴史の概要
    • Effientが副作用の懸念増によりつまずく
    • Brilintaが次のPlavixとなるのか
    • コレステロール降下剤:対PAD兵器庫における重要な武器
    • 初期的な有効性を示せなかった遺伝子治療
    • PAD治療における変革は幹細胞治療に希望を託す
    • プラセンタ由来幹細胞治療:有望なPAD治療法
    • 医療機器市場における技術革新および成長を引き起こす可能性を持つPAD
    • deCODE geneticsが主要な血管障害へのSNP関連感染性を発見
    • PADが男性よりも女性に多いことが明らかとなり神話が崩壊
  • 薬物治療用の入手可能な薬剤
  • 末梢動脈疾患(PAD):概要
  • 臨床研究/企業イニシアチブ
  • 主要な国際企業
    • 7TM Pharma A/S(デンマーク)
    • アンジェスMG(日本)
    • AstraZeneca Plc.(英国)
    • CardioVascular BioTherapeutics, Inc.(米国)
    • Cytokinetics, Inc.(米国)
    • Diffusion Pharmaceuticals LLC(米国)
    • Eli Lilly and Company(米国)
    • LTTバイオファーマ(日本)
    • miRagen Therapeutics, Inc.(米国)
    • Multi Gene Vascular Systems Ltd.(イスラエル)
    • 日産化学工業(日本)
    • 大塚製薬(日本)
    • Pluristem Therapeutics, Inc.(イスラエル)
    • ReNeuron Group PLC(英国)
    • Sanofi(フランス)
    • Sucampo Pharmaceuticals, Inc.(米国)
    • t2cure GmbH(ドイツ)
    • TCA Cellular Therapy, LLC(米国)
    • TheraVasc, Inc.(米国)
    • vasopharm GmbH(ドイツ)
  • 世界市場の展望

第3章 市場

  • 米国
  • カナダ
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • その他欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域

第4章 競合情勢

目次
Product Code: MCP-6815

This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 50 companies including many key and niche players such as 7TM Pharma A/S, AnGes MG, Inc., AstraZeneca Plc, CardioVascular BioTherapeutics, Inc., Cytokinetics, Inc., Diffusion Pharmaceuticals LLC, Eli Lilly and Company, LTT Bio-Pharma Co., Ltd., miRagen Therapeutics, Inc., Multi Gene Vascular Systems Ltd., Nissan Chemical Industries, Ltd., Otsuka Pharmaceutical Co., Ltd., Pluristem Therapeutics, Inc., ReNeuron Group PLC., Sanofi , Sucampo Pharmaceuticals, Inc., t2cure GmbH, TCA Cellular Therapy, LLC , TheraVasc, Inc., and vasopharm GmbH. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Low Awareness and Limited Pharmaceutical Options Typify PAD Market
  • Critical Limb Ischemia - An Insight
  • Growing Incidence, Rooted in Aging and Lifestyle- Related Issues, Drives the PAD Market
  • Inflating Elderly Population Forms Basis for PAD Therapeutics Market
    • Table 1: 2011 Global Population Statistics for the 65+ Age Group (includes corresponding Graph/Chart)
  • High Costs - A Cause of Concern
  • Anti-Platelet Drugs: Spearheading the Battle against PAD
  • Plavix Set to Lose Ground following Patent Expiry
  • A Peek into the History of Palvix
    • Table 2: Plavix Stands Second in the Global Pharma Industry: Ranking of Global Top 20 Pharma Brands in 2010 in Terms of Sales (USD Million) (includes corresponding Graph/Chart)
    • Table 3: Global Sales of Plavix: 2009 and 2010 (in US$ Millions) (includes corresponding Graph/Chart)
  • Effient Falters as Concerns with Side-Effects Grow
  • Will Brilinta be the New Plavix?
  • Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal
  • Gene Therapy Fails to Deliver on Initial Promise
  • Hopes Pinned on Stem Cell Therapy to Revolutionize PAD Treatment
  • Placenta-derived Stem Cell Therapy: A Promising Treatment for PAD
  • PAD Holds Potential to Spawn Innovation and Growth in Medical Devices Market
  • deCODE genetics Discovers SNP Linking Susceptibility to Major Vascular Diseases
  • Myth Busted as PAD Revealed to Target Greater Numbers of Females than Males

2. AVAILABLE DRUGS FOR PHARMACOLOGICAL TREATMENT

  • Plavix (Clopidogrel)
  • Prasugrel (Effient)
  • Ticagrelor (Brilinta)
  • Cilostazol (Pletal®)

3. PERIPHERAL ARTERIAL DISEASE (PAD) - AN OVERVIEW

  • Peripheral Arterial Disease: Understanding the Stealthy Peril
  • Causes of PAD
  • Tobacco Use
  • Diabetes
  • Dyslipidemia
  • Hypertension
  • Causes of PAD in Lower Extremities
  • Atherosclerosis
  • Blood Clotting
  • Link Established between Depression and PAD
  • Ethyl-EPA Intake Proves Favorable for PAD Sufferers
  • PAD Risk Factors
  • Symptoms of PAD
  • Claudication
  • Rest Pain
  • Other Symptoms
  • Prognosis of PAD
  • Diagnosis of PAD
  • Ankle Brachial Index (ABI)
  • Ankle-Brachial Index and Associated Severity of Peripheral Arterial Disease
  • Magnetic Resonance Angiography (MRA) and CT Scan
  • Control of PAD
  • Classification of PAD Severity
  • Treatment for PAD
  • Lifestyle Changes
  • Medication
  • Surgery
  • Methods for Avoiding PAD Complications
  • Conclusion

4. CLINICAL STUDIES/CORPORATE INITIATIVES

  • Shire Plc Acquires Pervasis Therapeutics
  • Aldagen Inc.'s ALD-301 Presents Positive Phase I/II Results in Critical Limb Ischemia Clinical Study
  • Cytokinetics Begins Phase IIa EoE Clinical Trial of Ck-2017357 in Patients with PAD and Claudication
  • NV1FGF Fails to Demonstrate Efficacy in Phase 3 Trials
  • Pervasis Commences Second Clinical Program Aimed at PAD
  • Taiwan Liposome and Ildong Pharm Tie Up to Market ProFlow for PAD
  • miRagen Therapeutics Enters into Licensing Agreement with t2cure
  • Pluristem Therapeutics Presents Positive Results for PLX-PAD
  • Unremarkable Statistical Results from Phase II Clinical Study of 6R-BH4 in Peripheral Arterial Disease
  • Aastrom Biosciences Reports Treatment of Final Patient in RESTORE-CLI Clinical Trial
  • Aastrom Biosciences Receives Fast Track Designation from FDA for Phase III CLI Program
  • Diffusion Pharmaceuticals Achieves Success in Phase I/II Clinical Trial of Trans Sodium Crocetinate in PAD
  • ReNeuron Group Provides Positive Results on ReN009 Stem Cell Therapy for PAD
  • AnGes MG Receives FDA Approval for Late Stage Trial of PAD Therapeutic
  • Effient Bags Approval in Europe

5. FOCUS ON SELECT GLOBAL PLAYERS

  • 7TM Pharma A/S (Denmark)
  • AnGes MG, Inc. (Japan)
  • AstraZeneca Plc. (UK)
  • CardioVascular BioTherapeutics, Inc. (US)
  • Cytokinetics, Inc. (US)
  • Diffusion Pharmaceuticals LLC (US)
  • Eli Lilly and Company (US)
  • LTT Bio-Pharma Co., Ltd. (Japan)
  • miRagen Therapeutics, Inc. (US)
  • Multi Gene Vascular Systems Ltd. (Israel)
  • Nissan Chemical Industries, Ltd. (Japan)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Pluristem Therapeutics, Inc. (Israel)
  • ReNeuron Group PLC (UK)
  • Sanofi (France)
  • Sucampo Pharmaceuticals, Inc. (US)
  • t2cure GmbH (Germany)
  • TCA Cellular Therapy, LLC (US)
  • TheraVasc, Inc. (US)
  • vasopharm GmbH (Germany)

6. GLOBAL MARKET PERSPECTIVE

    • Table 4: World Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics by Geographic Region/Country - US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 5: World Historic Review for Peripheral Arterial Disease Therapeutics by Geographic Region - US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 6: World 15-Year Perspective for Peripheral Arterial Disease Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2004, 2011, and 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current and Future Analysis
    • Market Potential
    • Market Overview
      • PAD Awareness Imperative for Market Growth
    • Table 7: US Pharmaceutical Market (2007-2011): Sales in US$ Millions for Lipitor, Plavix, Nexium, Abilify, Advair Diskus, Seroquel, Singulair, Crestor, Cymbalta, Humira, and Others (includes corresponding Graph/Chart)
      • Plavix® Granted Extension on US Market Exclusivity
      • Generics Set to Steal Market Share from Plavix
      • Repeat PAD Hospitalizations Contribute to Sky-High Treatment Costs
    • Select Regional Players
  • B. Market Analytics
    • Table 8: The US Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 9: The US Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Low Awareness and Knowledge Characterize the Canadian PAD Market
  • B. Market Analytics
    • Table 10: Canadian Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart) (includes corresponding Graph/Chart)
    • Table 11: Canadian Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
      • Up to 3.2 Million West-European Denizens Caught in the Web of Critical Limb Ischemia
      • The United Kingdom - Largest Market for PAD Therapeutics in Europe
    • Plavix® Faces Generic and Branded Competition in Europe
    • Table 12: Western Europe Plavix Comparative Sales 2010 and 2011 in US$ Millions
    • Table 13: Sales of Plavix across the EU (2011): Percentage Market Share Breakdown for Germany, France, UK, Spain, Greece, and Other EU Nations (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 14: European Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics by Country/Region - France, Germany, Italy, UK, Spain, Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 15: European Historic Review for Peripheral Arterial Disease Therapeutics by Country/Region - France, Germany, Italy, UK, Spain, Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 16: European 15-Year Perspective for Peripheral Arterial Disease Therapeutics by Country/Region - Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

3a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Sanofi - A Leading French Player
  • B. Market Analytics
    • Table 17: French Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 18: French Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

3b. GERMANY

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
    • Select Regional Players
  • B. Market Analytics
    • Table 19: German Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 20: German Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

3c. ITALY

  • Market Analysis
    • Table 21: Italian Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 22: Italian Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • Market Overview
    • Leading Players
  • B. Market Analytics
    • Table 23: UK Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 24: UK Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

3e. SPAIN

  • Market Analysis
    • Table 25: Spanish Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 26: Spanish Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

3f. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Select Regional Players
  • B. Market Analytics
    • Table 27: Rest of Europe Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 28: Rest of Europe Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

4. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Strong Growth Expected in Asia-Pacific for PAD Therapeutics
    • A Snapshot of Indian Market Opportunity
    • Strategic Corporate Development
    • Select Regional Players
  • B. Market Analytics
    • Table 29: Asia-Pacific Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 30: Asia-Pacific Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

5. LATIN AMERICA

  • Market Analysis
    • Table 31: Latin American Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 32: Latin American Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Select Regional Players
  • B. Market Analytics
    • Table 33: Rest of World Recent Past, Current and Future Analysis for Peripheral Arterial Disease Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 34: Rest of World Historic Review for Peripheral Arterial Disease Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top